CPT code 83993 denotes a lab-performed immunoassay that measures fecal calprotectin, used to help differentiate inflammatory bowel disease (IBD) from noninflammatory conditions such as irritable bowel syndrome (IBS). This laboratory procedure is clinically important because it provides a noninvasive marker of intestinal inflammation that can reduce reliance on endoscopy for initial triage and monitoring. National payers increasingly consider such assays in diagnostic pathways and coverage policies, influencing utilization and access.

Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of clinical context and service setting, typical billing and coding considerations, and what to look for in payer coverage policies. The summary highlights practice implications for clinicians ordering the test and for laboratory providers submitting claims, including where to seek payer-specific medical necessity criteria and documentation requirements.

This publication does not provide clinical recommendations but supplies the coding and service context needed to understand how CPT code 83993 fits into diagnostic workflows, reimbursement discussions, and policy updates at the national level.